What Patra Treats: Main Uses and Benefits

Patra is commonly used to help manage bacterial infections that create noticeable physiological strain and symptomatic burden, especially in situations where the bacterial strain is likely to be resistant to certain antibiotics. It is applied when appropriate for patients experiencing symptoms associated with acute or episodic changes.

This combination is considered relevant for managing infections of the ears, lungs, sinus, skin and soft tissue, and urinary tract.

Therapeutic Focus and Symptom Management

This medication is applied in addressing conditions characterized by symptoms that may intensify temporarily in the lower respiratory tract, such as pneumonia and acute exacerbations of COPD, and the associated symptoms related to systemic imbalance, like fever. Patra is also relevant across domains involving symptoms related to physical discomfort and inflammatory or irritative states, such as acute bacterial rhinosinusitis and cellulitis. Its use assists with managing the progression of the infection and supports the patient during episodes of heightened discomfort.

---

Quick Fact: Relief for Symptomatic Discomfort The medication may assist with managing the acute symptoms related to physical discomfort of ear infections and severe sinus pressure, helping patients cope more steadily with symptom fluctuations.

Regulatory References

1. NIH MedlinePlus Drug Information

Patra (Amoxicillin/Clavulanate) eligibility is strictly defined by regulatory authorities. The medication is contraindicated for any patient with a documented history of severe hypersensitivity reactions, such as anaphylaxis, to any penicillin or other beta-lactam antibiotic. It is also forbidden for those with a prior history of cholestatic jaundice or hepatic dysfunction specifically associated with this combination product.

Population Eligibility Rules

Category	Regulatory Status
Adults & Older Adults	Generally eligible; older adults may require dose adjustment for renal function.
Pediatric Use	Established for those 12 weeks (3 months) and older. Infants under 12 weeks require a specific, modified dosing regimen.
Mononucleosis	Use is not recommended due to an increased risk of a non-allergic rash.
Severe Renal Impairment	Requires dose adjustment; the extended-release tablet formulation is contraindicated.
Hepatic Impairment	Must be used with caution; liver function monitoring may be required.
Pregnancy/Lactation	Use is permitted only if clearly needed (Category B for pregnancy) and should be done with caution due to excretion into breast milk.

The official documentation for Patra, which contains the active ingredients Amoxycillin and Clavulanic Acid, identifies several important drug interaction classes and specific medications.

Interacting Medicines and Substance Categories

Interaction Type	Interacting Product or Class	Practical Implication based on Official Documentation
Effect on Anticoagulants	Warfarin	Close monitoring of clotting time is required due to potential changes in bleeding risk.
Effect on Contraception	Oral Contraceptive Pills (containing Ethinyl Estradiol)	The effectiveness of hormonal contraceptives may be reduced, necessitating the use of supplementary non-hormonal birth control methods.
Effect on Other Drugs	Methotrexate (chemotherapy agents)	Close patient and laboratory monitoring is required due to the potential for increased levels of Methotrexate in the body, which may lead to toxicity.
Co-administration Warnings	Doxycycline (and other bacteriostatic antibiotics)	Co-administration should be avoided or replaced with alternative antibiotics as the effectiveness of Patra may be diminished.

Regulatory Basis of Interaction Profile

Interactions documented in the regulatory label are primarily based on effects on drug plasma levels (pharmacokinetic changes) or direct functional antagonism. For instance, the interaction with Methotrexate is linked to altered renal elimination, requiring dose adjustments and monitoring for toxicity. The documented interaction with oral contraceptives reflects a known effect on the metabolism of hormonal birth control, potentially leading to a loss of efficacy. These official interaction statements classify combinations as those requiring close medical monitoring (e.g., Warfarin, Methotrexate) or those where co-administration should be avoided (e.g., Doxycycline), establishing constraints on use as mandated by official labeling.

Dual Action on Nerve Signals

Patra works through two primary and complementary biological mechanisms to modulate nerve signaling. This dual approach targets key pathways associated with regulating the transmission and intensity of signals within the central nervous system, leading to a systemic modulation of nerve signal transmission.

---

Activating Opioid Receptors

The drug acts as an agonist at specific mu-opioid receptors located on nerve cells in the brain and spinal cord. This molecular interaction directly engages the opioid system, initiating a cascade that reduces the excitability of nerve pathways and suppresses the flow of signals between neurons.

---

Norepinephrine Reuptake Inhibition

Simultaneously, Patra increases the effective concentration of the chemical messenger norepinephrine by inhibiting its reuptake transporter. This action enhances the body's natural descending inhibitory pathways—systems that modulate the transmission of signals traveling down the spinal cord—thereby contributing to a modulated state of nerve signal processing.

Patra is a combination medication with specific official guidelines for its administration. The medicine is primarily used via the oral route, encompassing tablets, extended-release tablets, and oral suspensions. An intravenous (IV) route is also approved for initial management of severe infections, which may then transition to oral therapy.

Dosing and Frequency

The exact dosage and frequency are determined by the specific product formulation and the fixed Amoxicillin-to-Clavulanic Acid ratio. Dosing regimens typically require administration either twice daily (every 12 hours) or three times daily (every 8 hours), depending on the strength selected. For instance, the higher-strength tablets are commonly prescribed on a twice-daily schedule.

Administration and Duration Rules

All oral forms of Patra must be administered at the start of a meal. This timing instruction is a specific requirement to minimize gastrointestinal upset and ensure optimal absorption of the Clavulanic Acid component. If the extended-release tablet form is used, it must be swallowed whole and not crushed or chewed. The standard course of treatment typically lasts between 7 and 14 days. The treatment must not be extended beyond 14 days without clinical review.

Population Adjustments

Dosing requires adjustment for patients with renal impairment (reduced kidney function), particularly for specific high-strength formulations and those with severely reduced Creatinine Clearance. However, dose adjustment is generally not required for older adults unless their renal function is compromised. Adherence to these strict labeled instructions defines the standardized protocol for the medicine’s use.

Research Evidence / Overview of Studies for Patra (Amoxicillin/Clavulanate)

The research base for Patra is largely built upon official scientific literature, including Randomized Controlled Trials (RCTs), systematic reviews, and meta-analyses. These studies have been conducted to assess outcomes for specific bacterial infections. These studies focus on documenting patient outcomes and changes in various measured symptoms, rather than offering predictions for individual cases.

---

Evidence for Use in Acute Respiratory and Ear Infections (ABRS and AOM)

Research was conducted exploring conditions associated with acute or disruptive episodes in the upper and middle respiratory tracts, specifically acute bacterial rhinosinusitis (ABRS, or sinus infections) and acute otitis media (AOM, or middle ear infections). Studies involving ABRS research examined outcomes related to physical discomfort, such as outcomes related to the clinical resolution of symptoms. For AOM, studies focused extensively on pediatric populations, where researchers monitored outcomes capturing phases of heightened symptom activity, such as the rates of clinical success or failure.

---

Evidence for Use in Lower Respiratory Tract Infections (CAP)

Research exploring community-acquired pneumonia (CAP) was evaluated in a significant number of systematic reviews and Randomized Controlled Trials. These studies included adults and older adults with mild to moderate CAP, encompassing both outpatients and those hospitalized outside of the Intensive Care Unit (ICU). The research highlights changes measured during defined follow-up intervals, typically up to 30 days, to assess the overall outcome in the observed populations. Research explores Patra's use in settings involving empirical treatment, where treatment begins before the exact causative organism is always confirmed.

---

What Is Still Uncertain About Patra Research

The primary evidence gap relates to the lack of head-to-head comparative evidence against some newer or alternative antibiotics across all indications. While research is ongoing in several areas, such as the optimal use in older adults with CAP, the overall evidence base often relies on indirect comparisons or retrospective data syntheses for certain populations. The evidence highlights what is known about its utility against resistant organisms, but evidence remains limited regarding its use in settings where resistance is not a primary concern.

Key Studies & References

1. NICE Guideline: Urinary tract infection (lower): antimicrobial prescribing

Common questions about Patra (FAQ)

Q: How is Patra different from similar over-the-counter medicines?

A: Patra is a prescription-only combination antibiotic. Its official documentation describes it as containing two active components, amoxicillin and clavulanic acid. The clavulanic acid works to protect the amoxicillin from being broken down by certain bacteria, allowing the medicine to overcome forms of bacterial resistance—a function not shared by single-component or most over-the-counter medications.

Q: Can Patra be used to treat other problems besides the ones listed?

A: Official regulatory documents indicate that the medicine is approved only for specific bacterial infections, such as those involving the respiratory tract, middle ear, and sinuses. Information regarding its use for any other conditions is not included in the official regulatory label.

Q: Do Patra side effects usually go away after a while?

A: Regulatory documents indicate that most common adverse effects, such as general stomach upset, have been observed to resolve in many patients. Serious effects, such as severe allergic reactions or liver problems, are rare but require consultation with a healthcare professional. Information suggests that cases of liver issues are generally observed to be reversible following discontinuation.

Q: Does Patra cause weight gain?

A: According to official product information, weight gain is not listed as a common, uncommon, or rare adverse reaction observed during clinical trials for Patra.

Q: What common supplements or vitamins might interact with Patra?

A: Interactions with common vitamins or general dietary supplements are not documented in the official regulatory drug label. However, the label notes specific interactions with prescription medicines such as warfarin (a blood thinner) and methotrexate, where regulatory guidelines call for close monitoring.

Q: Are there specific foods I should avoid while using Patra?

A: Official documentation does not typically list specific foods that must be avoided. The product information notes that this medicine is administered at the start of a meal, a condition intended to help minimize potential stomach upset and ensure proper absorption.

Q: How quickly does Patra start to work?

A: The active ingredients in Patra, amoxicillin and clavulanic acid, have a relatively short elimination half-life of approximately one to one and a half hours in individuals with normal kidney function. This is the time it takes for the drug's concentration in the body to be reduced by half.

Q: When can I expect to notice the full effect of Patra?

A: The official treatment course is typically 7 to 14 days and is not recommended to be extended beyond 14 days without clinical reassessment. Research evidence indicates that symptom improvement is generally observed during the course of treatment for the conditions it addresses.

Q: Is Patra appropriate for children?

A: Patra's use is officially established for pediatric patients aged 12 weeks (3 months) and older. Infants under 12 weeks require a specific, modified dosing regimen that is outlined in the official product information.

Q: Is Patra considered a controlled substance?

A: Patra is officially classified as a prescription-only medication in regulatory documentation. It is not designated as a controlled substance by major government drug agencies.

Q: Do you need lab tests before starting Patra?

A: While routine pre-treatment lab tests are not always stated as a general requirement, official warnings note that monitoring of liver function may be considered during prolonged use. Dose adjustments based on kidney function tests may also be necessary for patients with reduced kidney function.

Q: What is the recommended storage temperature for Patra?

A: Storage requirements differ based on the form. Tablets should be kept at controlled room temperature (20°C to 25°C). The liquid suspension, once mixed, requires mandatory refrigeration (2°C to 8°C) and must not be frozen to maintain its stability and effectiveness.

Q: Does Patra contain gluten or common allergens?

A: The product information states the drug is a penicillin derivative, meaning it is contraindicated for individuals with a known severe hypersensitivity to penicillin or related antibiotics. Additionally, the chewable tablets and liquid suspensions contain aspartame (a source of phenylalanine), which carries a specific warning for individuals with Phenylketonuria (PKU).

Q: Are there warnings about driving or operating machinery while on Patra?

A: Official documentation lists common adverse reactions that can affect the central nervous system, such as dizziness and headache. Due to potential effects, the product documentation advises caution regarding the performance of tasks that require concentration or operating machinery.

Q: Is Patra metabolized by the liver?

A: Yes, official pharmacokinetic data indicates that the clavulanic acid component of Patra undergoes considerable metabolism (processing) in the liver. The amoxicillin component is only partially metabolized and is mostly excreted unchanged by the kidneys.

Q: How long does Patra stay in the system after the last dose?

A: Pharmacokinetic data indicates that in adults with normal kidney function, both amoxicillin and clavulanic acid have a short elimination half-life of approximately one to one and a half hours. This is the time it takes for the concentration of the medicine in the body to be reduced by half.

Q: Why do some people need a higher dose of Patra than others?

A: Dosage is determined by several factors mentioned in official documents, including the severity and type of infection being treated and patient-specific factors. Notably, dose adjustment is required based on the patient's weight (especially in children) and the presence of reduced kidney function.

Q: Are there different brand names for the same active ingredient as Patra?

A: Yes. The active ingredients, Amoxicillin and Clavulanate Potassium, are the generic compound name for Patra. This combination is available under various brand names worldwide, such as Augmentin.

Storage and Disposal Requirements

Storage conditions for Amoxicillin/Clavulanate (Patra) are strictly defined by formulation and temperature to maintain stability.

Temperature and Handling

Formulation	Required Storage Condition	Stability Limit
Tablets/Dry Powder	Controlled room temperature (20 C to 25 C), away from excess moisture.	Until expiration date.
Reconstituted Suspension	Mandatory refrigeration (2 C to 8 C). Do not freeze.	Must be discarded after 10 days of mixing.

All forms must be kept in the original, tightly closed container and protected from moisture and light. The medicine must be stored out of the sight and reach of children.

Disposal of Unused Medicine

Any expired or unused product must be discarded according to official regulatory guidelines, such as those provided by the FDA. The medicine must not be disposed of in wastewater or household waste to limit environmental release.